TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Concurrent Bupropion / Varenicline for Smoking Cessation
Brief Summary: This study focuses on the first step in developing an algorithm for maximizing quit-smoking success based on an adaptive approach, which changes treatment from the initial nicotine replacement therapy (NRT) when that treatment alone may not be sufficient. These NRT "non-responders" are switched (in double-blind fashion) before the quit date to receive either varenicline alone or varenicline paired with bupropion. Some participants who would otherwise have failed at their quit smoking attempt could be "rescued" by switching to alternative pharmacotherapies. The proposed study will evaluate the combination treatment against varenicline alone in an adaptive trial design


Options:
A: Arm Label: Extended Patch Treatment; Type: EXPERIMENTAL; Interventions: Drug: 24-weeks of nicotine patch | Arm Label: Standard Patch Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Patch Treatment | Intervention Type: DRUG; Name: Standard Patch Treatment; Assigned to Arm(s): Standard Patch Treatment | Intervention Type: DRUG; Name: 24-weeks of nicotine patch; Assigned to Arm(s): Extended Patch Treatment
B: Arm Label: Active bupropion-Active gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + nicotine gum | Arm Label: Active bupropion-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Active bupropion-Placebo gum | Arm Label: Placebo medication-Placebo gum; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo bupropion-Placebo gum | Intervention Type: DRUG; Name: bupropion + nicotine gum; Assigned to Arm(s): Active bupropion-Active gum | Intervention Type: DRUG; Name: Active bupropion-Placebo gum; Assigned to Arm(s): Active bupropion-Placebo gum | Intervention Type: DRUG; Name: Placebo bupropion-Placebo gum; Assigned to Arm(s): Placebo medication-Placebo gum
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Selegiline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Selegiline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Concurrent Bupropion / Varenicline for Smoking Cessation
Brief Summary: This study focuses on the first step in developing an algorithm for maximizing quit-smoking success based on an adaptive approach, which changes treatment from the initial nicotine replacement therapy (NRT) when that treatment alone may not be sufficient. These NRT "non-responders" are switched (in double-blind fashion) before the quit date to receive either varenicline alone or varenicline paired with bupropion. Some participants who would otherwise have failed at their quit smoking attempt could be "rescued" by switching to alternative pharmacotherapies. The proposed study will evaluate the combination treatment against varenicline alone in an adaptive trial design


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: nortriptyline | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: transdermal nicotine | Intervention Type: DRUG; Name: nortriptyline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: transdermal nicotine; Assigned to Arm(s): 2
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
C: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
D: Arm Label: 1 Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: 2 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab
Brief Summary: Evaluation of the efficacy and safety of eculizumab in symptomatic or transfusion-dependent patients with untreated or refractory hemolytic cold agglutinin disease(CAD)


Options:
A: Arm Label: Eculizumab; Type: EXPERIMENTAL; Interventions: Drug: Eculizumab | Intervention Type: DRUG; Name: Eculizumab; Assigned to Arm(s): Eculizumab
B: Arm Label: Treatment arm; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Rituximab | Intervention Type: DRUG; Name: Bendamustine, Rituximab; Assigned to Arm(s): Treatment arm
C: Intervention Type: DRUG; Name: prednisone, low dose rituximab; Assigned to Arm(s): N/A
D: Arm Label: M281 administered every 4 weeks (double-blind period); Type: EXPERIMENTAL; Interventions: Drug: M281, Drug: Placebo | Arm Label: M281 administered every 2 weeks (double-blind period); Type: EXPERIMENTAL; Interventions: Drug: M281 | Arm Label: Placebo administered every 2 weeks (double-blind period); Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: M281 administered every 4 weeks (open-label extension period); Type: EXPERIMENTAL; Interventions: Drug: M281 | Arm Label: M281 administered every 2 weeks (open-label extension period); Type: EXPERIMENTAL; Interventions: Drug: M281 | Intervention Type: DRUG; Name: M281; Assigned to Arm(s): M281 administered every 2 weeks (double-blind period), M281 administered every 2 weeks (open-label extension period), M281 administered every 4 weeks (double-blind period), M281 administered every 4 weeks (open-label extension period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): M281 administered every 4 weeks (double-blind period), Placebo administered every 2 weeks (double-blind period)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrated Cardiac Care and Palliative Homecare for Patients With Severe Heart Failure
Brief Summary: Patients with severe heart failure have as many symptoms as many patients with cancer but yet do not have equal access to supportive and palliative care. They have an unpredictable course of illness, which makes difficult to judge when the palliative stage has been reached. The Heart failure and Palliative care Programme is a three-year project in Sweden financed by the Swedish Association of Local Authorities and Regions (SALAR). The overall aim is to develop, implement and evaluate a model that integrates cardiac care and palliative advanced home care for patients with severe chronic heart failure. The primary aim is to study the effects on patients' symptom burden, quality of life and activities of daily living. A randomized controlled clinical study is planned.

Patients (n=62) with a confirmed diagnosis in accordance with the criteria proposed by the European Society of Cardiology and with NYHA III-IV symptoms and at least one of following criteria will be included;

1. At least one episode of worsening heart failure that resolved with injection / infusion of diuretics or the addition of other heart failure treatment in the last 6 months and regarded optimally treated according to the responsible physician.
2. Need for infusions-treatment.
3. Chronic poor quality of life (VAS \< 50)
4. Signs of cardiac cachexia (involuntary non-oedematous weight loss ≥ 6% of total body weight within the last 6-12 months)
5. less than one year life expectancy The participants will be randomized to intervention or control group. The intervention consist of a multidisciplinary approach and collaboration between specialist palliative and heart failure (HF) caregivers, in a shared structured person-centred and identity-promoting care at home during six months. Usual care is performed for the control group.


Options:
A: Arm Label: Active Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Support | Arm Label: Usual HF Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual HF Care | Intervention Type: BEHAVIORAL; Name: Behavioral Support; Assigned to Arm(s): Active Intervention | Intervention Type: BEHAVIORAL; Name: Usual HF Care; Assigned to Arm(s): Usual HF Care
B: Intervention Type: BEHAVIORAL; Name: Patient-Centered Advance Care Planning; Assigned to Arm(s): N/A
C: Arm Label: Integrated care; Type: EXPERIMENTAL; Interventions: Other: Integrated care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated care; Assigned to Arm(s): Integrated care | Intervention Type: OTHER; Name: Integrated care; Assigned to Arm(s): Integrated care
D: Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention (ACP) arm; Type: EXPERIMENTAL; Interventions: Behavioral: ACP | Intervention Type: BEHAVIORAL; Name: ACP; Assigned to Arm(s): Intervention (ACP) arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety During Use of Paediatric Triple Chamber Bag Formulas, Administered IV at a Weight Dependant Dose During 5 Consecutive Days, in Paediatric Patients up to 18 Years Requiring Parenteral Nutrition.
Brief Summary: The primary objective of this study was to provide daily information on the performance safety of the Ped3CB in practical therapeutic use in pediatric patients.


Options:
A: Arm Label: Amino acid based infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Amino acid based infant formula | Arm Label: Extensively hydrolyzed casein infant formula; Type: EXPERIMENTAL; Interventions: Other: Extensively hydrolyzed casein infant formula | Arm Label: Mother's own breast milk; Type: OTHER; Interventions: Other: Mother's own breast milk | Intervention Type: OTHER; Name: Amino acid based infant formula; Assigned to Arm(s): Amino acid based infant formula | Intervention Type: OTHER; Name: Extensively hydrolyzed casein infant formula; Assigned to Arm(s): Extensively hydrolyzed casein infant formula | Intervention Type: OTHER; Name: Mother's own breast milk; Assigned to Arm(s): Mother's own breast milk
B: Arm Label: New Amino Acid formula; Type: EXPERIMENTAL; Interventions: Other: New Amino Acid formula | Arm Label: Control formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Commercially available Amino Acid Formula | Intervention Type: OTHER; Name: New Amino Acid formula; Assigned to Arm(s): New Amino Acid formula | Intervention Type: OTHER; Name: Commercially available Amino Acid Formula; Assigned to Arm(s): Control formula
C: Arm Label: Cysteine; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Parenteral cysteine-HCl supplementation | Arm Label: No-cysteine placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo - added premasol | Intervention Type: DIETARY_SUPPLEMENT; Name: Parenteral cysteine-HCl supplementation; Assigned to Arm(s): Cysteine | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo - added premasol; Assigned to Arm(s): No-cysteine placebo
D: Arm Label: parenteral nutrition solution; Type: OTHER; Interventions: Drug: Ped3CB | Intervention Type: DRUG; Name: Ped3CB; Assigned to Arm(s): parenteral nutrition solution

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Femoral Artery In-Stent Restenosis (FAIR) Trial
Brief Summary: Comparison of recurrent-restenosis rates 6 months after angioplasty of in-stent restenoses or in-stent reocclusions in the superficial femoral artery (SFA) using either a standard balloon (Admiral Xtreme, Invatec) or a paclitaxel-eluting balloon (In.Pact™ Admiral, Invatec).


Options:
A: Arm Label: Paclitaxel eluting balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: drug eluting balloon angioplasty | Arm Label: Standard balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: standard balloon angioplasty | Intervention Type: DEVICE; Name: drug eluting balloon angioplasty; Assigned to Arm(s): Paclitaxel eluting balloon | Intervention Type: DEVICE; Name: standard balloon angioplasty; Assigned to Arm(s): Standard balloon angioplasty
B: Arm Label: Standart balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: Admiral Xtreme | Arm Label: Paclitaxel-eluting balloon arm; Type: ACTIVE_COMPARATOR; Interventions: Device: In.Pact Admiral | Intervention Type: DEVICE; Name: Admiral Xtreme; Assigned to Arm(s): Standart balloon angioplasty | Intervention Type: DEVICE; Name: In.Pact Admiral; Assigned to Arm(s): Paclitaxel-eluting balloon arm
C: Arm Label: conventional PTA; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA, Procedure: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: PTA with PEB; Type: EXPERIMENTAL; Interventions: Device: PTA with PEB, Procedure: Percutaneous Transluminal Angioplasty (PTA) | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): conventional PTA | Intervention Type: DEVICE; Name: PTA with PEB; Assigned to Arm(s): PTA with PEB | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): PTA with PEB, conventional PTA
D: Arm Label: Endoprosthesis; Type: EXPERIMENTAL; Interventions: Device: GORE VIABAHN® Endoprosthesis | Arm Label: Plain old balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: Plain old balloon angioplasty | Intervention Type: DEVICE; Name: GORE VIABAHN® Endoprosthesis; Assigned to Arm(s): Endoprosthesis | Intervention Type: DEVICE; Name: Plain old balloon angioplasty; Assigned to Arm(s): Plain old balloon angioplasty

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E, Against Severe Rotavirus Gastroenteritis in Infants
Brief Summary: The trial is a phase III randomized, double-blind, placebo-controlled trial with the primary objective of evaluating the efficacy of three doses of ORV 116E, 10\^5.0 FFU, against severe rotavirus gastroenteritis, in comparison with a placebo in India.


Options:
A: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group
B: Arm Label: Oral Rotavirus Vaccine 116E (ORV 116E); Type: EXPERIMENTAL; Interventions: Biological: ORV 116E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: ORV 116E; Assigned to Arm(s): Oral Rotavirus Vaccine 116E (ORV 116E) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Bivalent OPV 2 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 2 week interval | Arm Label: Bivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bivalent OPV 4 week interval | Arm Label: Monovalent OPV 2week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 2 week interval | Arm Label: Monovalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Monovalent OPV 4 week interval | Arm Label: Trivalent OPV 4 week interval; Type: ACTIVE_COMPARATOR; Interventions: Biological: Trivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 2 week interval; Assigned to Arm(s): Bivalent OPV 2 week interval | Intervention Type: BIOLOGICAL; Name: Bivalent OPV 4 week interval; Assigned to Arm(s): Bivalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 2 week interval; Assigned to Arm(s): Monovalent OPV 2week interval | Intervention Type: BIOLOGICAL; Name: Monovalent OPV 4 week interval; Assigned to Arm(s): Monovalent OPV 4 week interval | Intervention Type: BIOLOGICAL; Name: Trivalent OPV 4 week interval; Assigned to Arm(s): Trivalent OPV 4 week interval
D: Arm Label: Rotavirus vaccine (BRV-PV); Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine (BRV-PV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotavirus vaccine (BRV-PV); Assigned to Arm(s): Rotavirus vaccine (BRV-PV) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E, Against Severe Rotavirus Gastroenteritis in Infants
Brief Summary: The trial is a phase III randomized, double-blind, placebo-controlled trial with the primary objective of evaluating the efficacy of three doses of ORV 116E, 10\^5.0 FFU, against severe rotavirus gastroenteritis, in comparison with a placebo in India.


Options:
A: Arm Label: Oral Rotavirus Vaccine 116E (ORV 116E); Type: EXPERIMENTAL; Interventions: Biological: ORV 116E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: ORV 116E; Assigned to Arm(s): Oral Rotavirus Vaccine 116E (ORV 116E) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: rotavirus vaccine 116E 1 X 10(4); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Arm Label: rotavirus vaccine 116E 1 X 10(5); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Intervention Type: BIOLOGICAL; Name: Oral Rotavirus Vaccine 116E Live Attenuated; Assigned to Arm(s): rotavirus vaccine 116E 1 X 10(4), rotavirus vaccine 116E 1 X 10(5)
C: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Biological: Tritanrix-HB+Hib, Biological: Polio Sabin | Intervention Type: BIOLOGICAL; Name: Rotarix; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group | Intervention Type: BIOLOGICAL; Name: Tritanrix-HB+Hib; Assigned to Arm(s): Placebo Group, Rotarix Group | Intervention Type: BIOLOGICAL; Name: Polio Sabin; Assigned to Arm(s): Placebo Group, Rotarix Group
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E, Against Severe Rotavirus Gastroenteritis in Infants
Brief Summary: The trial is a phase III randomized, double-blind, placebo-controlled trial with the primary objective of evaluating the efficacy of three doses of ORV 116E, 10\^5.0 FFU, against severe rotavirus gastroenteritis, in comparison with a placebo in India.


Options:
A: Intervention Type: BIOLOGICAL; Name: 2-dose oral live attenuated G1P[8] human rotavirus vaccine; Assigned to Arm(s): N/A
B: Arm Label: Group 1, RotaTeq® x 3; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq® | Arm Label: Group 5, Rotarix®, RotaTeq® x2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 4, Rotarix® x 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotarix® | Arm Label: Group 2, RotaTeq®, Rotarix® x 2; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Arm Label: Group 3, RotaTeq® x 2, Rotarix®; Type: EXPERIMENTAL; Interventions: Biological: Rotarix®, Biological: RotaTeq® | Intervention Type: BIOLOGICAL; Name: Rotarix®; Assigned to Arm(s): Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 4, Rotarix® x 2, Group 5, Rotarix®, RotaTeq® x2 | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1, RotaTeq® x 3, Group 2, RotaTeq®, Rotarix® x 2, Group 3, RotaTeq® x 2, Rotarix®, Group 5, Rotarix®, RotaTeq® x2
C: Arm Label: Oral Rotavirus Vaccine 116E (ORV 116E); Type: EXPERIMENTAL; Interventions: Biological: ORV 116E | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: ORV 116E; Assigned to Arm(s): Oral Rotavirus Vaccine 116E (ORV 116E) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Rotarix Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group

Answer: C